Literature DB >> 8435356

Management of bowel obstruction in advanced and terminal cancer patients.

C Ripamonti1, F De Conno, V Ventafridda, B Rossi, M J Baines.   

Abstract

BACKGROUND: Bowel obstruction is a common and distressing outcome in patients with abdominal or pelvic cancer. PATIENTS AND
METHOD: Patients may develop bowel obstruction at any time in their clinical history, with an incidence ranging from 5.5% to 42% in ovarian carcinoma and from 10% to 28.4% in colorectal cancer. The causes of the obstruction may be benign postoperative adhesions, a focal malignant or benign deposit, relapse or diffuse carcinomatosis. The symptoms which are almost always present are intestinal colic (reported in 72%-76% of patients), abdominal pain due to distension, hepatomegaly or tumor masses (in 92% of patients) and vomiting (68%-100%) of cases.
CONCLUSION: While surgery must remain the primary treatment for malignant obstruction, it is now recognised that there is a group of patients with advanced disease or poor general condition who are unfit for surgery and require alternative management to relieve distressing symptoms. A number of treatment options are now available for the patient with advanced cancer who develops intestinal obstruction. In this review of the literature, the indications for surgery will be examined, the use of nasogastric tube and percutaneous gastrostomy evaluated and the place of drugs for symptom control described.

Entities:  

Mesh:

Year:  1993        PMID: 8435356     DOI: 10.1093/oxfordjournals.annonc.a058345

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  21 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  [Paralytic ileus due to vinorelbine].

Authors:  Gaspar Esquerdo Galiana; Hugo Briceño García; Cristina Llorca Ferrándiz; José Manuel Cervera Grau
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

Review 3.  Palliative percutaneous endoscopic gastrostomy placement for gastrointestinal cancer: Roles, goals, and complications.

Authors:  Matthew Mobily; Jitesh A Patel
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

Review 4.  [Pharmacological treatment of malignant bowel obstruction in severely ill and dying patients : a systematic literature review].

Authors:  C Klein; S Stiel; J Bükki; C Ostgathe
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

5.  Why not octreotide?

Authors:  S Mercadante
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

Review 6.  Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer.

Authors:  Sarah E Cousins; Emma Tempest; David J Feuer
Journal:  Cochrane Database Syst Rev       Date:  2016-01-04

7.  Management of bowel obstruction in patients with stage IV cancer: predictors of outcome after surgery.

Authors:  Valerie Francescutti; Austin Miller; Yashodhara Satchidanand; Amy Alvarez-Perez; Kelli Bullard Dunn
Journal:  Ann Surg Oncol       Date:  2012-09-19       Impact factor: 5.344

Review 8.  A Systematic Review of the Clinical Presentation, Diagnosis, and Treatment of Small Bowel Obstruction.

Authors:  Srinivas R Rami Reddy; Mitchell S Cappell
Journal:  Curr Gastroenterol Rep       Date:  2017-06

9.  Bowel obstruction in home-care cancer patients: 4 years experience.

Authors:  S Mercadante
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

10.  A scoring system for the prognosis and treatment of malignant bowel obstruction.

Authors:  Jon C Henry; Severin Pouly; Rachael Sullivan; Suhail Sharif; Dori Klemanski; Sherif Abdel-Misih; Nicole Arradaza; David Jarjoura; Carl Schmidt; Mark Bloomston
Journal:  Surgery       Date:  2012-08-26       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.